Other Urinary, Phase I
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anne Chiang, MD, PhD
- David Schoenfeld, MD, PhD
- David A. Braun, MD, PhD
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Harriet Kluger, MD
- Jeffrey Ishizuka, MD, DPhil
- John Glendening
- Marianne Davies, NP, DNP, MSN, BSN
- Mario Sznol, MD
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- So Yeon Kim, MD
- Thuy Tran, MD, PhD
- Vanna Dest
- Last Updated10/23/2024
- Study HIC#2000034639